机构：[1]Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China浙江大学医学院附属第一医院[2]Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration Of Traditional Chinese Medicine Of PR China, Hangzhou, China[3]Key Laboratory Of Multiple Organ Transplantation, Ministry Of Health, Hangzhou, China[4]Key Laboratory Of Nephropathy, Zhejiang Province, Hangzhou, China[5]Department of Biochemistry, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China[6]Centre for Genomic Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China[7]Shenzhen Institute of Research and Innovation, The University of Hong Kong, Shenzhen, Guangdong, China[8]Department of Epidemiology, College of Medicine, Zhejiang University, Hangzhou, China[9]Institute of Translational Medicine, College of Medicine, Zhejiang University, Hangzhou, China
Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment. We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored. These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.
基金：
National Fund Committee of China [81470938, 81200546]; Dr Cheng Yu Tung Fellowships
第一作者机构：[1]Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China[2]Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration Of Traditional Chinese Medicine Of PR China, Hangzhou, China[3]Key Laboratory Of Multiple Organ Transplantation, Ministry Of Health, Hangzhou, China[4]Key Laboratory Of Nephropathy, Zhejiang Province, Hangzhou, China
共同第一作者：
通讯作者：
通讯机构：[1]Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China[2]Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration Of Traditional Chinese Medicine Of PR China, Hangzhou, China[3]Key Laboratory Of Multiple Organ Transplantation, Ministry Of Health, Hangzhou, China[4]Key Laboratory Of Nephropathy, Zhejiang Province, Hangzhou, China[6]Centre for Genomic Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China[8]Department of Epidemiology, College of Medicine, Zhejiang University, Hangzhou, China
推荐引用方式(GB/T 7714)：
Qu Lihui,Lu Yingying,Ying Meike,et al.Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients[J].Oncotarget.2017,8(46):81285-81294.doi:10.18632/oncotarget.18150.
APA：
Qu, Lihui,Lu, Yingying,Ying, Meike,Li, Bingjue,Weng, Chunhua...&Huang, Hongfeng.(2017).Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients.Oncotarget,8,(46)
MLA：
Qu, Lihui,et al."Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients".Oncotarget 8..46(2017):81285-81294
医学